You are here: Industry Insights > CanSino Biologics

News List

COVID-19 vaccine safely induces immune response in Chinese trial europeanpharmaceuticalreview
July 22, 2020
Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.
Sartorius Supports Development of Vaccine Candidate against Coronavirus americanpharmaceuticalreview
March 30, 2020
Sartorius has supported CanSino Biologics and Maj. Gen. Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences ...
CanSinoBIO, Synairgen get regulatory approval for Covid-19 trials pharmaceutical-technology
March 20, 2020
China-based CanSino Biologics has received regulatory approval to conduct Phase I clinical trial of recombinant novel coronavirus vaccine (adenovirus type 5 vector) candidate.
National Research Council contribution plays key role in newly approved Ebola vaccine biospace
March 21, 2018
In response to the Ebola outbreak that claimed more than 10,000 lives in West Africa four years ago, Canada and China worked on a new Ebola vaccine